Hospital Virgen de la Salud

healthcaređź“Ť Toledo, Spain
OpenAlex Profile
2
Alpha-gal Syndrome Publications
0
Alpha-gal Syndrome Researchers

Associated Institutions

Complejo Hospitalario Universitario de Toledo
parent
Hospital Universitario de Toledo
successor

Publications

A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders.

de la Fuente J, Urra JM, Contreras M, Pacheco I, Ferreras-Colino E, et al.
F1000Research •

Humans evolved by losing the capacity to synthesize the glycan Galα1-3Galβ1-(3)4GlcNAc-R (α-Gal), which resulted in the development of a protective response mediated by anti-α-Gal IgM/IgG/IgA antibodies against pathogens containing this modification on membrane proteins. As an evolutionary trade-off, humans can develop the alpha-Gal syndrome (AGS), a recently diagnosed disease mediated by anti-α-Gal IgE antibodies and associated with allergic reactions to mammalian meat consumption and tick bites. However, the anti-α-Gal antibody response may be associated with other immune-mediated disorders such as those occurring in patients with COVID-19 and Guillain-Barré syndrome (GBS). Here, we provide a dataset (209 entries) on the IgE/IgM/IgG/IgA anti-α-Gal antibody response in healthy individuals and patients diagnosed with AGS, tick-borne allergies, GBS and COVID-19. The data allows correlative analyses of the anti-α-Gal antibody response with factors such as patient and clinical characteristics, record of tick bites, blood group, age and sex. These analyses could provide insights into the role of anti-α-Gal antibody response in disease symptomatology and possible protective mechanisms.

View on PubMed →DOI →

Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.

Roca JM, Alonso V, Pericay C, Escudero P, Salud A, et al.
Chemotherapy •

We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. 126 patients from 19 centers were included from July 2006 to July 2007 in this prospective non-controlled study. Irinotecan-refractory metastatic colorectal cancer patients with Karnofsky >or=70 received cetuximab 500 mg/m(2) every 2 weeks (q2w) in combination with irinotecan 180 mg/m(2) q2w until disease progression or unacceptable toxicity. The primary endpoint was the progression-free rate at 12 weeks. Median age was 65 years; 65.9% male; colon/rectum 64.3/34.1%; Karnofsky status <or=80/>or=90% in 45.3/54.7% of the patients. The progression-free rate was 42.7 (95% CI 32.8-52.6) and 22.4% (95% CI 14.2-30.7) at 12 and 24 weeks, respectively. The main grade 3 or 4 toxicities were: diarrhea 13.5% and acne-like rash 10.3%. No grade 3 or 4 infusional or allergic reactions were reported. The progression-free rates confirm that cetuximab q2w in combination with irinotecan is an option, and is as active and safe as the standard weekly regimen.

View on PubMed →DOI →